China’s New Bribery Law May Strengthen Medical Sector Crackdown

Select Language:

China is planning to step up its anti-corruption initiatives within the healthcare industry following the issuance of a new legal interpretation aimed at strengthening existing laws on bribery and corruption. This update, issued on April 10 and set to take effect on May 1, clarifies that corporate bribery within the medical sector will face stricter penalties.

Additionally, the new interpretation specifies that the standards for prosecuting individuals in non-government roles who accept bribes should align with those for government officials. As a result, the minimum monetary threshold for criminal charges against ordinary medical professionals accepting kickbacks has been reduced from 60,000 CNY (approximately $8,800) to 30,000 CNY (about $4,400).

While these legal clarifications increase the perceived deterrent effect of criminal statutes in healthcare, they are not merely about lowering the bar to conviction. Legal experts emphasize that comprehensive judgments should consider enforcement standards, ensuring fair application of the laws.

With these updated guidelines, authorities will have a clearer foundation to target commercial bribery cases in the medical field. A common problematic practice involves providing hospitals with equipment free of charge, coupled with exclusive agreements for high-priced consumables, which often leads to criminal investigations.

For instance, regulatory agencies in Yantai City, Shandong Province, uncovered a case in March involving a medical distributor that supplied a hospital with six testing devices at no cost since 2020. In exchange, the hospital agreed to purchase all related consumables exclusively from this distributor, which generated over 6.1 million CNY (around $900,000) in sales by June 2024.

As a penalty, the distributor was fined 100,000 CNY (approximately $14,600), and its illicit gains were confiscated. With the new legal interpretation, such covert illegal activities could be addressed through criminal law, with the possibility of retroactive accountability extending back five or even 20 years in serious cases.

This behavior falls under the category of commercial bribery under the Anti-Unfair Competition Law. If the involved company holds a dominant market position, it could also face charges under antitrust statutes, according to legal experts.